– USA, NJ – Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC/CYCCP), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Dr. Ken Ferguson (Ph.D.) to its Board of Directors.
Dr. Ferguson will represent the 6% Convertible Exchangeable Preferred stockholders.
“We are very pleased to welcome Ken to our Board of Directors. As a highly accomplished scientist with extensive drug development experience, he will provide significant expertise and insight to help guide our ongoing clinical development programs and advance our company’s pipeline,” said Board Chairman, D. Chris Henney.
About Dr. Kenneth M. Ferguson
Dr. Ferguson’s professional experience includes over 30 years of scientific and drug development experience in the biopharmaceutical industry. Currently, he serves as an Operating Partner at Accelerator Life Science Partners. Previously, he was CSO of EMulate Therapeutics, where he was responsible for the investigation of magnetic field effects on cell processes to enable novel therapeutic strategies. He previously spent seven years with Omeros Corp, where he last held the position of Chief Development Officer. Earlier in his career, he spent over seventeen years with ICOS Corp, culminating in his appointment as President in 2007 where he oversaw the integration of ICOS into Eli Lilly & Co. Before he was appointed President, he served in multiple roles within ICOS, including as Vice President, Therapeutic Development, as well as COO, CSO, and Member of the Board of Managers of Lilly ICOS LLC where he was responsible for strategic management. He has authored or co-authored 26 scientific papers and eight issued patents.
“Cyclacel has made tremendous progress in developing fadraciclib and CYC140, novel and highly differentiated cancer therapies with competitive product profiles to address a broad range of solid tumors and blood cancers,” said Dr. Ferguson. “With fadraciclib, the leading CDK2/9 inhibitor, and CYC140 advancing through Phase 1/2 clinical studies, I look forward to contributing to Cyclacel’s mission in providing tolerated, oral therapies to patients suffering from cancer.”
Dr. Ferguson earned a B.S. in Biological Sciences from Cornell University and received his Ph.D. in Pharmacology from the University of Texas Health Science Center. He completed his post-doctoral study at the Cold Spring Harbor Laboratory.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation, and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel’s strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications.
For more information: https://cyclacel.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.